Food and Drug Administration or FDA approved Advanced Accelerator Applications' NETSPOT, a kit used by the local radiopharmacy to reconstitute an injection, which uses radioactive diagnostic agent, Gallium Ga 68 dotatate. NETSPOT is all set to become a preferred diagnostic drug kit for NET patients I believe that solid ramp up of NETSPOT in USA can prove to be a significant growth opportunity for the company in 2017. In this article, I will present my rationale for considering Advanced Accelerator Applications as a solid buy opportunity in 2017. With Advanced Accelerator Applications launching multiple products across geographies and securing reimbursement, these revenue numbers are expected to rise significantly in 20. The company reported a compounded average growth rate of 29.5% in its revenues from 2012 to 2015. In 2015, Advanced Accelerator Applications posted revenues close to €88.6 million. The company is also moving closer to launching its first MNM therapy, Lutathera, for neuroendocrine tumor or NET patients both in USA and European Union. This radiopharmaceutical company currently markets seven diagnostic products in the European market and recently launched one of its products in USA.īesides these commercialized diagnostic drug kits, Advanced Accelerator Applications also boasts of six investigational candidates in its research pipeline. Advanced Accelerator Applications offers positron emission tomography or PET and single-photon emission computed tomography or SPECT products which are used to diagnose conditions in areas such as neurology, oncology, cardiology, infectious diseases, and inflammation.
Since last few years, the company has been steadily increasing its presence in USA. IRE and IRE ELiT currently employ 250 people.Advanced Accelerator Applications ( NASDAQ: AAAP) is a leader in the European molecular nuclear medicine or MNM segment.
In 2020, the group devoted 15% of its turnover to R&D, a percentage which has been steadily increasing since the company's creation. In addition to its production activities, the IRE contributes to protection and environmental monitoring through its services of measuring radioactivity in various samples, radiological characterisation of waste and contaminated elements and consultancy and technical assistance in the fields of radiology and nuclear energy.įor its part, IRE ELiT is IRE's innovation subsidiary founded in 2010 to develop radiopharmaceuticals used for imaging and treatment of certain cancers and palliative care. The IRE is the world leader in the production of molybdenum-99, the "parent" isotope of metastable technetium-99, and the most widely used in nuclear medicine for many examinations (heart, bone, lungs, thyroid, brain, kidneys, etc). The IRE or the National Institute for Radioelements is a public utility foundation, whose main activity is the production of radioisotopes for diagnostic and therapeutic applications in the field of nuclear medicine.
#NETSPOT AAA GENERATOR#
**GalliEo is the name of the generator in the US and countries without Marketing Authorization.ĥ0 years dedicated to excellence in nuclear medicine *Also called GalliAd, Galliad and Germanio (68Ge)cloruro/Gallio(68Ga) depending on the marketed country. SmPC of both products are available here: More information about IRE ELiT’s 68Ge/68Ga generator in the technical information sheet below. In parallel, the FDA (Food and Drug Administration) has also approved the NETSPOT® application with the Galli Eo®** generator for the US. The approval of SomaKit TOC® reconstitution with our Galli Ad® generator is an important step to achieve this ambition, facilitating the whole procedure for the radiopharmacist”. Erich Kollegger, General Manager of IRE and IRE ELiT, comments: “We have designed our generator especially for cold kits, in order to enable doing PET imaging with Ga-68 as simply as SPECT imaging with Tc-99.
0 kommentar(er)
